IQVIA Holdings Inc. (IQV) Net Income CAGR:3.83%(TTM)
The net income cagr for IQVIA Holdings Inc. (IQV) is +3.83% over the latest trailing 12-month period. Net income CAGR uses precomputed financial statement history.
The net income cagr for IQVIA Holdings Inc. (IQV) stock is 3.83% over the past 12 months. The 3 year average growth rate is 9.49% and the 5 year cagr is 27.63%. Net income CAGR shows how IQVIA Holdings Inc.'s bottom-line profitability has grown. This reflects the company's ability to convert revenue into profits after all expenses.
IQV Net Income CAGR Chart
IQVIA Holdings Inc. (IQV)
IQV Net Income CAGR History
| Year | Start Net Income | End Net Income | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $1.37B | $1.36B | $-13.00M | -0.95% | -0.95% |
| 2024 | $1.36B | $1.37B | +$15.00M | +1.10% | +1.10% |
| 2023 | $1.09B | $1.36B | +$267.00M | +24.47% | +24.47% |
| 2022 | $966.00M | $1.09B | +$125.00M | +12.94% | +12.94% |
| 2021 | $279.00M | $966.00M | +$687.00M | +246.24% | +246.24% |
| 2020 | $191.00M | $279.00M | +$88.00M | +46.07% | +46.07% |
| 2019 | $259.00M | $191.00M | $-68.00M | -26.25% | -26.25% |
| 2018 | $1.31B | $259.00M | $-1.05B | -80.21% | -80.21% |
| 2017 | $115.00M | $1.31B | +$1.19B | +1038.26% | +1038.26% |
| 2016 | $387.20M | $115.00M | $-272.20M | -70.30% | -70.30% |
| 2015 | $356.38M | $387.20M | +$30.82M | +8.65% | +8.65% |
| 2014 | $226.59M | $356.38M | +$129.79M | +57.28% | +57.28% |
| 2013 | $177.55M | $226.59M | +$49.05M | +27.62% | +27.62% |
| 2012 | $241.77M | $177.55M | $-64.23M | -26.56% | -26.56% |
| 2011 | $160.60M | $241.77M | +$81.18M | +50.55% | +50.55% |
Quarterly Net Income — QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $274.00M | -46.7% | +10.0% |
| Q4 2025 | $514.00M | +55.3% | +17.6% |
| Q3 2025 | $331.00M | +24.4% | +16.1% |
| Q2 2025 | $266.00M | +6.8% | -26.7% |
| Q1 2025 | $249.00M | -43.0% | -13.5% |
| Q4 2024 | $437.00M | +53.3% | -6.8% |
| Q3 2024 | $285.00M | -21.5% | -5.9% |
| Q2 2024 | $363.00M | +26.0% | +22.2% |
| Q1 2024 | $288.00M | -38.6% | -0.3% |
| Q4 2023 | $469.00M | +54.8% | +106.6% |
| Q3 2023 | $303.00M | +2.0% | +7.1% |
| Q2 2023 | $297.00M | +2.8% | +16.0% |
| Q1 2023 | $289.00M | +27.3% | -11.1% |
| Q4 2022 | $227.00M | -19.8% | -28.6% |
| Q3 2022 | $283.00M | +10.5% | +8.4% |
| Q2 2022 | $256.00M | -21.2% | +46.3% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About IQVIA Holdings Inc.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Ari Bousbib